Loading
A phase 1/2 trial of Doxorubicin in basal cell carcinoma, run by SkinJect, Inc., active and no longer recruiting.
Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II) is a phase 1/2 interventional study registered as NCT04928222 by SkinJect, Inc., with 25 participants enrolled, started 2021-09-24 and due to reach its primary completion in 2023-12-30. Interventions recorded: Doxorubicin-containing MNA and Placebo-containing MNA.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Doxorubicin, Cytotoxic chemotherapy and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Shares Doxorubicin, Cytotoxic chemotherapy and the tag pipeline.
Shares Doxorubicin, Cytotoxic chemotherapy and the tag pipeline.
Shares Doxorubicin, Cytotoxic chemotherapy and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Shares Basal cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/